Description:
Axitinib (AG013736) is a tyrosine kinase inhibitor developed by Pfizer. Axitinib is a tyrosine kinase inhibitor that blocks the activation of VEGFR1, VEGFR2, VEGFR3, c-kit, and PDGFRβ (IC50 = 1.2, 0.25, 0.29, 1.7, and 1.6 nM, respectively). It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models.
- Molecular Weight: 386.5
- Molecular Formula: C22H18N4OS
Purity: ≥98%
Canonical SMILES:
O=C(NC)C1=C(SC2=CC3=C(C(/C=C/C4=NC=CC=C4)=NN3)C=C2)C=CC=C1
InChI:
InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
InChIKey: RITAVMQDGBJQJZ-FMIVXFBMSA-N
- Boiling Point: 668.9±55.0 °C at 760 mmHg
- Solubility: Soluble to 25 mM in DMSO.
- Appearance: Off-White to Pale Beige Solid
- Application: Protein Kinase Inhibitors
- Storage: -20°C Freezer
Synonyms:
AG 013736; N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide; Inlyta
More details are to be found on supplier website
